

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignina 22313-1450 www.uspto.gov

FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. 038602/1140 1137 04/11/2001 Klaus Peter Hirth 09/829,968 7590 07/02/2003 Beth A. Burrous **EXAMINER FOLEY & LARDNER** HOLLERAN, ANNE L Washington Harbour 3000 K Street, N.W., Suite 500 ART UNIT PAPER NUMBER Washington, DC 20007-5109 1642 DATE MAILED: 07/02/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>	Application No.	Applicant(s)
Office Action Summary	09/829,968	HIRTH, KLAUS PETER
	Examiner	Art Unit
	Anne Holleran	1642
The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) Responsive to communication(s) filed on 177	is action is non-final.	•
, <u> </u>		osecution as to the merits is
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims  AVM Claim(a) 20.35 and 27 in/ore panding in the application		
4)⊠ Claim(s) <u>20-25 and 27</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
· · · · · · · · · · · · · · · · · · ·		
6)⊠ Claim(s) <u>20-25 and 27</u> is/are rejected. 7)□ Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.		
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>		
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>		
Attachment(s)		
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449) Paper No(s)</li> </ol>	5) 🔲 Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01)

Page 2

Application/Control Number: 09/829,968

Art Unit: 1642

## **DETAILED ACTION**

1. The amendment filed April 17, 2003 is acknowledged. Claim 26 was canceled. Claims 25 and 27 were amended.

Claims 20-25 and 27 are pending and examined on the merits.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

# Claim Rejections Withdrawn::

4. The rejection of claim 25 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in view of the amendment.

## Claim Rejections Maintained:

5. The rejection of claim 27 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention is maintained for the reasons of record.

Applicant's response fails to address the failing of the specification to teach what constitutes an "abnormal presence" of the labeled ligand in a bodily fluid. Because the label will

Art Unit: 1642

be found in all bodily fluids whether there is metastasis or not, it is not clear that the specification apprises one of skill in the art how to detect metastasis by the dection of label in a bodily fluid.

6. The rejection of claims 20-25 under 35 U.S.C. 103(a) as being unpatentable over Boocock (J. Nat. Cancer Inst., 87(7): 506-516, 1995) in view of Ferrara (WO 94/10202; published 11 May 1994) is maintained for the reasons of record.

Applicant argues that because Boocock demonstrates the detection of VEGF in cancers that are known to be metastatic that this does not suggest the claimed methods where the methods are performed on patients where it is unknown whether the tumor is metastatic. This argument is unpersuasive, because the teachings of Boocock establish the association between VEGF and the condition of metastasis. Now that this association has been established, using the detection of VEGF as a way of detecting metastasis is obvious, especially in view of teachings establishing that methods of VEGF detection are known in the art. Therefore, the rejection is maintained.

#### Conclusion

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Page 4

Application/Control Number: 09/829,968

Art Unit: 1642

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action: In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the Office should be directed to Anne Holleran, Ph.D. whose telephone number is (703) 308-8892. Examiner Holleran can normally be reached Monday through Friday, 9:30 am to 2:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, Ph.D. can be reached at (703) 308-3995.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at telephone number (703) 308-0196.

Anne L. Holleran Patent Examiner June 29, 2003

8

ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600